Ascendis Pharma A/S’s (ASND) Equal Weight Rating Reiterated at Morgan Stanley

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $116.00 target price on the biotechnology company’s stock. Morgan Stanley’s price target would suggest a potential downside of 19.91% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Citigroup boosted their price objective on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research note on Thursday, February 8th. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Monday, December 25th. Finally, JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.25.

Ascendis Pharma A/S Trading Up 1.9 %

Shares of ASND opened at $144.83 on Monday. The firm’s 50-day moving average price is $149.15 and its 200-day moving average price is $125.48. The firm has a market capitalization of $8.43 billion, a price-to-earnings ratio of -15.66 and a beta of 0.50. Ascendis Pharma A/S has a 1-year low of $66.03 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The business had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. On average, research analysts forecast that Ascendis Pharma A/S will post -4.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ASND. Avior Wealth Management LLC raised its holdings in shares of Ascendis Pharma A/S by 12.8% during the third quarter. Avior Wealth Management LLC now owns 7,177 shares of the biotechnology company’s stock valued at $672,000 after purchasing an additional 814 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Ascendis Pharma A/S by 26.3% during the third quarter. Handelsbanken Fonder AB now owns 11,367 shares of the biotechnology company’s stock valued at $1,064,000 after purchasing an additional 2,367 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Ascendis Pharma A/S by 17.4% during the third quarter. Harbor Capital Advisors Inc. now owns 14,135 shares of the biotechnology company’s stock valued at $1,324,000 after purchasing an additional 2,092 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Ascendis Pharma A/S by 53.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 14,990 shares of the biotechnology company’s stock valued at $1,404,000 after purchasing an additional 5,229 shares during the last quarter. Finally, Brown Advisory Inc. raised its holdings in shares of Ascendis Pharma A/S by 2.7% during the third quarter. Brown Advisory Inc. now owns 510,109 shares of the biotechnology company’s stock valued at $47,767,000 after purchasing an additional 13,227 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.